• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Recurrent Myocarditis Induced by Immune-Checkpoint Inhibitor Treatment Is Accompanied by Persistent Inflammatory Markers Despite Immunosuppressive Treatment.

作者信息

Aghel Nazanin, Gustafson Dakota, Di Meo Ashley, Music Milena, Prassas Ioannis, Seidman Michael A, Hansen Aaron R, Thavendiranathan Paaladinesh, Diamandis Eleftherios P, Delgado Diego, Fish Jason E

机构信息

Division of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, Ted Rogers Program in Cardiotoxicity Prevention, University Health Network, Toronto, ON, Canada.

Division of Cardiology, Cardio-oncology Program, Juravinski Hospital, McMaster University, Hamilton, ON, Canada.

出版信息

JCO Precis Oncol. 2021 Mar 11;5. doi: 10.1200/PO.20.00370. eCollection 2021 Mar.

DOI:10.1200/PO.20.00370
PMID:34337287
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8238280/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfa2/8238280/ce2b774fcb48/po-5-po.20.00370-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfa2/8238280/9580f97e3013/po-5-po.20.00370-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfa2/8238280/850fa6a4096c/po-5-po.20.00370-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfa2/8238280/ce2b774fcb48/po-5-po.20.00370-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfa2/8238280/9580f97e3013/po-5-po.20.00370-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfa2/8238280/850fa6a4096c/po-5-po.20.00370-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfa2/8238280/ce2b774fcb48/po-5-po.20.00370-g003.jpg

相似文献

1
Recurrent Myocarditis Induced by Immune-Checkpoint Inhibitor Treatment Is Accompanied by Persistent Inflammatory Markers Despite Immunosuppressive Treatment.免疫检查点抑制剂治疗诱发的复发性心肌炎，尽管进行了免疫抑制治疗，但仍伴有持续性炎症标志物。
JCO Precis Oncol. 2021 Mar 11;5. doi: 10.1200/PO.20.00370. eCollection 2021 Mar.
2
Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.免疫检查点抑制剂相关心肌炎：表现与机制。
J Clin Invest. 2021 Mar 1;131(5). doi: 10.1172/JCI145186.
3
Monitoring of the Evolution of Immune Checkpoint Inhibitor Myocarditis With Cardiovascular Magnetic Resonance.利用心血管磁共振监测免疫检查点抑制剂相关性心肌炎的演变
Circ Cardiovasc Imaging. 2020 Nov;13(11):e010633. doi: 10.1161/CIRCIMAGING.120.010633. Epub 2020 Nov 6.
4
Troponin-guided utilization of methylprednisolone pulse, intravenous immunoglobulin, and mycophenolate mofetil for successful control of immune checkpoint inhibitor-related myocarditis.肌钙蛋白指导下使用甲泼尼龙冲击治疗、静脉注射免疫球蛋白和霉酚酸酯成功控制免疫检查点抑制剂相关心肌炎。
J Dermatol. 2024 Jun;51(6):e207-e208. doi: 10.1111/1346-8138.17113. Epub 2024 Jan 12.
5
Immune Checkpoint Inhibitor Myocarditis With Normal Cardiac Magnetic Resonance Imaging: Importance of Cardiac Biopsy and Early Diagnosis.心脏磁共振成像正常的免疫检查点抑制剂相关性心肌炎：心脏活检及早期诊断的重要性
Can J Cardiol. 2021 Oct;37(10):1654-1656. doi: 10.1016/j.cjca.2020.12.022. Epub 2020 Dec 26.
6
Association between myocarditis and other immune-related adverse events secondary to immune checkpoint inhibitor use.免疫检查点抑制剂使用继发的心肌炎与其他免疫相关不良事件之间的关联。
Int J Cancer. 2020 Sep 15;147(6):1753-1754. doi: 10.1002/ijc.32960. Epub 2020 May 6.
7
Immune checkpoint inhibitor-associated myocarditis: from pathophysiology to rechallenge of therapy - a narrative review.免疫检查点抑制剂相关性心肌炎：从病理生理学到治疗再挑战 - 一篇叙述性综述。
Future Cardiol. 2023 Feb;19(2):91-103. doi: 10.2217/fca-2022-0120. Epub 2023 Apr 20.
8
Subclinical Myocarditis After Combination Immune Checkpoint Inhibitor Therapy.联合免疫检查点抑制剂治疗后的亚临床心肌炎
Circ Heart Fail. 2021 Feb;14(2):e007524. doi: 10.1161/CIRCHEARTFAILURE.120.007524. Epub 2021 Jan 22.
9
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.免疫检查点抑制剂相关致死性心肌炎报告增加。
Lancet. 2018 Mar 10;391(10124):933. doi: 10.1016/S0140-6736(18)30533-6.
10
Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity.根据临床严重程度制定使用免疫检查点抑制剂或联合抗血管内皮生长因子治疗的心肌炎患者的治疗策略。
Eur J Cancer. 2021 Nov;157:10-20. doi: 10.1016/j.ejca.2021.07.023. Epub 2021 Aug 28.

引用本文的文献

1
Left Ventricular Thrombosis in Immune Checkpoint Inhibitor Myocarditis Mimicking ST-Segment Elevation Myocardial Infarction.免疫检查点抑制剂相关性心肌炎合并左心室血栓形成，酷似ST段抬高型心肌梗死
JACC Case Rep. 2024 Nov 6;29(21):102663. doi: 10.1016/j.jaccas.2024.102663.
2
Current Immunotherapy Treatments of Primary Breast Cancer Subtypes.原发性乳腺癌亚型的当前免疫治疗方法
Biomedicines. 2024 Apr 18;12(4):895. doi: 10.3390/biomedicines12040895.
3
Immune Checkpoint Inhibitors-Related Myocarditis: A Review of Reported Clinical Cases.

本文引用的文献

1
A proteome-wide immuno-mass spectrometric identification of serum autoantibodies.血清自身抗体的全蛋白质组免疫质谱鉴定
Clin Proteomics. 2019 Jun 20;16:25. doi: 10.1186/s12014-019-9246-0. eCollection 2019.
2
Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area.与免疫检查点抑制剂相关的心脏并发症：这一重要新兴领域文献的系统综述。
Can J Cardiol. 2018 Aug;34(8):1059-1068. doi: 10.1016/j.cjca.2018.03.012. Epub 2018 Mar 28.
3
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.
免疫检查点抑制剂相关心肌炎：已报道临床病例综述
Diagnostics (Basel). 2023 Mar 25;13(7):1243. doi: 10.3390/diagnostics13071243.
4
Artificial intelligence and imaging: Opportunities in cardio-oncology.人工智能与成像：心脏肿瘤学中的机遇。
Am Heart J Plus. 2022 Mar;15. doi: 10.1016/j.ahjo.2022.100126. Epub 2022 Apr 6.
5
Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis.免疫检查点抑制剂治疗后的心血管毒性：一项系统评价与荟萃分析。
Transl Oncol. 2022 May;19:101383. doi: 10.1016/j.tranon.2022.101383. Epub 2022 Mar 3.
免疫检查点抑制剂治疗患者的心肌炎。
J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764. doi: 10.1016/j.jacc.2018.02.037. Epub 2018 Mar 19.
4
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.免疫检查点抑制剂相关致死性心肌炎报告增加。
Lancet. 2018 Mar 10;391(10124):933. doi: 10.1016/S0140-6736(18)30533-6.
5
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.管理免疫检查点抑制剂相关毒性：癌症免疫治疗学会（SITC）毒性管理工作组的共识建议。
J Immunother Cancer. 2017 Nov 21;5(1):95. doi: 10.1186/s40425-017-0300-z.
6
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.Durvalumab 用于 III 期非小细胞肺癌放化疗后的治疗。
N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.
7
Fulminant Myocarditis with Combination Immune Checkpoint Blockade.暴发性心肌炎合并免疫检查点阻断治疗
N Engl J Med. 2016 Nov 3;375(18):1749-1755. doi: 10.1056/NEJMoa1609214.
8
Sequential high-content profiling of the IgG-autoantibody repertoire reveals novel antigens in rheumatoid arthritis.IgG自身抗体库的连续高内涵分析揭示类风湿性关节炎中的新抗原。
Arthritis Res Ther. 2016 Oct 12;18(1):235. doi: 10.1186/s13075-016-1135-6.
9
Immune complexome analysis reveals the specific and frequent presence of immune complex antigens in lung cancer patients: A pilot study.免疫复合物组分析揭示肺癌患者中免疫复合物抗原的特异性及频繁存在：一项初步研究。
Int J Cancer. 2017 Jan 15;140(2):370-380. doi: 10.1002/ijc.30455. Epub 2016 Oct 17.
10
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.与 CTLA4 和 PD1 阻断免疫疗法相关的心脏毒性。
J Immunother Cancer. 2016 Aug 16;4:50. doi: 10.1186/s40425-016-0152-y. eCollection 2016.